Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Tuyaerts, Sandra" or (type exact bookEditor and editor="Tuyaerts, Sandra")

Add to list
- Journal Article
- A1
- open access
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, An M. T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens (UGent) , Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, et al.

(2023) CANCER IMMUNOLOGY IMMUNOTHERAPY. 72(2). p.475-491
Add to list
2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer : the PRIMMO phase II trial

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, Ann M.T. van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, et al.

(2022) INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. In International Journal of Gynecological Cancer 32(Supplement 2). p.A187-A188
Add to list
- Conference Paper
- C3
Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, Ann M.T. Van Nuffel, Lien Lippens (UGent) , An Hendrix (UGent) , P. Vuylsteke, S. Henry, X.B. Trinh, P.A. Van Dam, S. Aspeslagh, et al.

(2021) ANNALS OF ONCOLOGY. In Annals of Oncology 32(Supplement 7). p.S1449-S1450
Add to list
- Journal Article
- A1
- open access
PRIMMO study protocol : a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer

Sandra Tuyaerts, An MT Van Nuffel, Eline Naert (UGent) , Peter A Van Dam, Peter Vuylsteke, Alex De Caluwé, Sandrine Aspeslagh, Piet Dirix, Lien Lippens (UGent) , Emiel De Jaeghere (UGent) , et al.

(2019) BMC CANCER. 19.
Add to list
- Conference Paper
- C3
PRIMMO study : combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer

Sandra Tuyaerts, An Van Nuffel, Peter Van Dam, Peter Vuylsteke, Alex De Caluwé, Piet Dirix, Katrien Vandecasteele (UGent) and Hannelore Denys (UGent)

(2017) Cancer Immunotherapy, 3rd CRI-CIMT-EATI-AACR international conference, Abstracts.
Add to list
Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols

Melissa Dullaers (UGent) , Karine Breckpot, Sonja Van Meirvenne, Aude Bonehill, Sandra Tuyaerts, Annelies Michiels, Lieven Straetman, Carlo Heirman, Catherine De Greef, Pierre Van Der Bruggen, et al.

(2004) MOLECULAR THERAPY. 10(4). p.768-779

Academic Bibliography

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study

2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer : the PRIMMO phase II trial

Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma

PRIMMO study protocol : a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer

PRIMMO study : combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer

Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols

Contents

Support

Contact